Melinta therapeutics, inc. /new/ (MLNT)
CashFlow / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Operating activities
Net loss

-157,192

-58,916

-73,932

-78,676

-61,649

-45,034

-24,226

-21,220

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

16,901

451

497

624

77

39

47

75

Bargain purchase gain

0

27,663

0

-

-

-

-

-

Adjustments to liability for potential royalties

-

-

-

-3,971

-

-

-

-

Change in fair value of tranche assets and liabilities

0

0

-1,313

-2,721

-

-

-

-

Non-cash interest expense

-25,673

-5,091

-2,010

-1,441

-

-

-

-

Allocated Share-based Compensation Expense

3,465

6,450

2,515

1,785

3,105

3,211

-

-

Share-based compensation

-

-

-

-

-

-

1,669

443

Change in fair value of warrant & conversion liabilities

-33,226

-335

-781

-42

-120

217

-87

-4

Change in fair value for IDB contingent liabilities

-8,817

0

0

-

-

-

-

-

Amortization of debt issuance costs

-

-

-

-

767

650

355

-

Loss on extinguishment of debt

-2,595

-607

0

-

-

-

-

-

Reversal of loss contract

5,330

0

0

-

-

-

-

-

Provision for inventory obsolescence

8,042

0

0

-

-

-

-

-

Write off of deferred equity finance costs

0

0

969

-

-

-

-

-

Asset impairment

26,076

0

0

231

-

-

-

-

Other

0

-70

0

-12

-

-

-

-

Amortization of debt issuance costs

-

-

-

-

-

-

-

394

Changes in operating assets and liabilities:
Receivables

5,044

3,140

-43

228

724

1,626

-

-

Inventory

17,541

10,825

0

-

-

-

-

-

Prepaid expenses and other current assets and liabilities

-2,180

-600

1,461

-458

-

-

-

-

Prepaid expenses

-

-

-

-

2,980

142

-19

-4

Deposits

-

-

-

-

13

11

311

-43

Accounts payable

8,285

-1,269

-21

-2,874

5,620

4,101

-809

-

Accounts payable

-

-

-

-

-

-

-

1,434

Accrued expenses

1,445

12,014

-1,840

-2,418

611

49

53

413

Accrued interest on notes payable

4,202

110

-14

119

-

-

-

-

Deferred revenues

0

1,000

0

-

-

-

-

-

Deposits on inventory

-40,773

0

0

-

-

-

-

-

Accrued payroll and benefits

-

-

-

-

553

438

183

101

Deferred revenues

-

-

-

9,008

5,661

5,664

-

-

Other non-current assets and liabilities

2,486

-157

-122

744

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-18,314

Investing activities
Net cash used in operating activities

-171,545

-75,598

-70,580

-72,554

-49,092

-32,440

-23,106

-

Cash acquired in merger with Cempra, Inc.

0

161,410

0

-

-

-

-

-

IDB acquisition

166,382

0

0

-

-

-

-

-

Purchases of intangible assets

2,000

5,500

0

-

-

-

-

-

Purchases of property and equipment

1,690

849

463

688

52

134

8

13

Proceeds from borrowing on long-term debt

-

-

-

-

3,000

5,238

-

10,000

Payment of long-term debt

-

-

-

-

-

238

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-13

Financing activities
Net cash provided by (used in) investing activities

-170,072

155,061

-463

-688

-52

-134

-8

-

Proceeds from the issuance of notes payable

111,421

38,844

44,111

10,000

-

-

-

-

Proceeds from the issuance of convertible notes payable to related party

0

24,526

0

-

-

-

-

5,000

Payment of offering costs

-

-

-

-

-

-

-

880

Costs associated with the issuance of notes payable

6,455

0

0

-

35

300

-

306

Proceeds from the issuance of warrants

33,264

0

0

-

-

-

-

-

Proceeds from the issuance of royalty agreement

1,472

0

0

-

-

-

-

-

Purchase of notes payable disbursement option

7,609

0

0

-

-

-

-

-

Proceeds from exercise of stock options and warrants

-

-

-

-

351

61

-

-

Proceeds from exercise of stock options and warrants

-

-

-

-

-

-

-

69

Proceeds from Issuance of Common Stock

51,452

0

0

-

-

-

-

-

Proceeds from issuance of common stock, net

155,273

0

0

-

-

-

-

-

Debt extinguishment

2,150

1,240

0

-

-

-

-

-

IDB acquisition deferred payments

1,633

0

0

-

-

-

-

-

Proceeds from the exercise of stock options, net of cancellations

3

88

65

365

-

-

34

-

Proceeds from the issuance of convertible preferred stock

0

0

13,625

82,991

-

-

-

-

Proceeds from issuance of common stock, net of underwriting discounts

-

-

-

-

48,535

54,407

78,289

-

Payment of preferred stock issuance costs

0

0

9

92

97

200

702

-

Deferred stock issuance costs

-

-

-

405

-

-

-

-

Repayment of notes payable

40,000

24,503

5,498

-

-

-

-

-

Net cash provided by financing activities

295,038

37,715

52,294

92,859

51,754

58,969

77,621

-

Net cash provided by financing activities

-

-

-

-

-

-

-

13,882

Net change in cash and equivalents

-46,579

117,178

-18,749

19,617

2,610

26,394

54,506

-4,445

Supplemental cash flow information:
Cash paid for interest

13,259

2,326

2,411

1,600

1,579

1,208

920

-

Cash received from exchange of state tax credits, net

0

283

207

-

-

-

-

-

Supplemental disclosure of non-cash financing and investing activities:
Accrued notes payable exit fee

-

-

-

175

-

-

-

-

Accrued purchases of fixed assets

10

2,155

12

135

-

-

-

-

Accrued notes payable issuance costs

0

0

475

559

-

-

-

-

Accretion of redeemable convertible preferred shares

-

-

-

-

-

-

313

-

Accretion of redeemable convertible preferred shares

-

-

-

-

-

-

-

3,763

Allocation of the convertible note proceeds to warrant

-

-

-

-

-

-

-

852

Allocation of the long-term debt proceeds to warrant

-

-

-

-

-

461

-

273

Reclassification of additional paid-in capital to warrant liability

-

-

-

-

-

241

-

-

Conversion of convertible notes payable and accrued interest into common stock

-

-

-

-

-

-

4,724

-

Conversion of redeemable convertible preferred shares into common stock

-

-

-

-

-

-

94,827

-

Reclassification of warrant liability to additional paid-in capital

-

-

-

-

801

-

1,033

-